$ALLK Allakos Inc. (NASDAQ:ALLK), a clinical-stage biopharmaceutical company developing therapeutic monoclonal antibodies for treatment of inflammatory, and proliferative diseases, faced a setback with disappointing results from a crucial phase 3 trial named Enigma 2 and phase 2/3 Kryptos trial.
Should you invest in the Company or watch from the sidelines?
Read on to find out more! https://www.aviseanalytics.com/should-allakos-inc-be-on-your-investment-watchlist/